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Ethical Governance of Gene Editing Technology
Abstract
Gene editing technology has been one of the breakthrough technologies for life science research. With
the application in biomedical research, healthcare, food and agriculture field, related ethical issues are
also concerned. This study summarized the research and application progress of gene editing technology
involving ethical issues in recent years. Based on sorting out the international discussions, attitudes, and
explorations about gene editing ethics issues, after analyzing the current status, discussions, and
measures of applications of gene editing technology on human beings in China, we propose five
suggestions about the ethical governance system construction of gene editing technology for China.
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Abstract: Gene editing technology has become one of the breakthrough technologies for life science research. With
therapid development of it’s applications in biomedical research, healthcare, food, and agriculture fields, gene
editing-related ethical issues have drawn much attention. Here we summarize the recent progress of gene editing
research and application, and gene editing-related ethical issues. We first focus on the international discussions, attitudes and explorations on the ethical governance associated with this Technology. We next analyze the current
status of ethical discussions and governance on gene editing applications in China. Finally, we propose five suggestions about the system construction of ethical governance on gene editing in China. DOI: 10.16418/j.issn.10003045.20210316002-en
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Gene editing technology represented by CRISPR has been
one of the breakthrough technologies for life science research. However, the advancing research and application of
gene editing have aroused wide ethical issues concerns, especially for the application to human beings. At the beginning
of 2013, studies showed that gene editing technology can be
used to edit human stem cell genes [1,2] and to modify the
entire organism (zebrafish) [3], which aroused the related
①
ethical concerns [4]. In 2015, the CRISPR/Cas9 technique
was for the first time applied to the editing of human embryos, triggering a heated discussion on ethical and regulatory issues concerning gene editing technology. In November
2018, the birth of gene-edited babies climaxed the discussions on ethical issues and governance system construction of
gene editing. This study summarized the recent progress of
gene editing research and application, and gene editingrelated ethical issues reviewed the international discussions
and explorations on ethical governance, and provided suggestions for the ethical governance system construction of
gene editing technology for China.

1 Ethical issues triggered by the research and
application of gene editing technology
With the application of gene editing technology in

biomedical research, healthcare, food and agriculture field,
related ethical issues are also concerned.

1.1 Rapid advancement of research and application of gene editing technology
Since the advent of CRISPR technique in 2013, gene editing technology has been booming, and the related research
papers have been surging. According to the data from Web of
Science Core Collection, there have been nearly 30 000 papers related to gene editing technology by 2020, with an
average annual growth rate over 20%.
For the research on the genetic mechanism of human development, the use of model animals has certain limitations [5], while gene editing technology shows significant
advantages. The research on gene editing of human embryos
focuses on the mechanism of embryogenesis by knocking out
important genes and the possibility of repairing genetic loci
associated with underlying genetic diseases. In gene repair of
genetic diseases, therapeutic embryo gene editing has cured
such diseases as cataract [6], tyrosinemia [7] and myodystrophy [8] in mouse models. However, a few studies applying
gene editing technology to human embryos have provoked
disputes within the academic community over the necessity
of those studies and over the rationality of the risk-reward
ratio, despite their compliance with related ethical codes. For
example, Fan’s team edited the CCR5 gene in zygotes to
explore treatment for AIDS [9]. Ma et al. [10] edited the
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MYBPC3 gene to seek treatment options for hypertrophic
cardiomyopathy (HCM). Fogarty et al. [5] knocked out the
Oct4 (POU5F1) gene in zygotes to study the abnormal development of embryos.
The clinical application of human somatic cell gene editing has made it possible to treat diseases with no other effective therapies. The phase I clinical trial of CRISPR
gene-edited T cells in patients with cancer, conducted by Lu
et al. [11] in West China Hospital of Sichuan University, has
demonstrated the feasibility of the clinical application of this
technology. Editas Medicine and Allergan have completed
②
the dosing of the first patient in phase I/II clinical trial of
the CRISPR medicine AGN-151587 (EDT-101) for treating
the genetic eye disease Leber congenital amaurosis (LCA10).
Intellia Therapeutics and Regeneron Pharmaceuticals are the
first companies in the world to have completed the dosing of
the first patient with transthyretin amyloidosis (ATTR) in
phase I clinical trial of the gene editing therapeutic agent
NTLA-2001, showing good interim results [12]. In October
2021, Intellia Therapeutics received U.S. Food and Drug
Administration (FDA) orphan drug designation for the ther③
apy . Additionally, β-thalassemia and sickle cell anemia
have been cured by the gene editing therapy co-developed by
CRISPR Therapeutics and Vertex Pharmaceuticals [13]. We
can see that gene editing technology shows great potential in
the treatment of diseases. Meanwhile, some researchers have
pointed out that caution is needed in the direct use of
CRISPR/Cas9 technology in vivo considering the technical
shortcomings and safety risks.
The application of gene editing technology in such fields
as crop breeding and food improvement develops faster than
that in human body. The United States Department of Agriculture (USDA) will no longer impose additional regulations
on gene-edited crops. By the end of 2020, the USDA has
approved more than 70 gene-edited crops. In December 2020,
the Ministry of Health, Labour and Welfare of Japan approved the application for the sale of gene-edited tomatoes
containing more γ-aminobutyric acid (GABA), which are
④
expected to be available on the market as early as 2022 .

1.2

Ethnical issues related to gene editing

With the rapid development of gene editing technology,
the research on related ethical issues is also underway. The
ethical issues related to gene editing can be discussed at the
technical, social and ecological levels.
(1) At the technical level, the ethical issues related to gene

editing mainly concern the uncertainties in the application
due to the unsound technology. The risks of gene editing
technology mainly include off-target effect (edits in the
wrong place) [14], mosaicism (some cells carry the edit but
others do not due to the insufficient editing) [15], immune
response caused by the entry of the CRISPR/Cas9 system
into human body [16], and unpredictable side effects caused by
the editing of specific functional genes [17,18]. Alanis-Lobato
et al. [19] have detected a large number of mutations around
POU5F1 in 22% of cells, including DNA rearrangement and
deletion of thousands of bases. After Zuccaro et al. [20] corrected EYS2 mutations with CRISPR/Cas9, about half of
embryos lost a large number of chromosome segments, some
even lost the whole chromosome. Liang et al. [21] discovered
that although gene conversion can be used for gene correction, the conversion tracks may expand beyond the target
region, leading to an extensive loss of heterozygosity (LOH),
which presents a serious safety risk. These risks and their
possible consequences are still uncertain, and it is difficult to
make clear the risk-reward of this technology.
(2) At the social level, the application of gene editing
technology may affect social equity and justice, causing
alienation of human dignity and thus raising ethical issues
concerning social development. Sociologists and ethicists
have discussed the ethical issues about gene editing technology from three aspects. ① Possible negative effects produced by gene selection. In view of the unclear boundaries of
the clinical application of gene editing technology, parents
may select certain human traits through prenatal testing and
gene editing, thereby worsening prejudice and insularity
which already exist in the society. ② The impact on family
values and common interests. Parents are the most appropriate surrogate medical decision maker before their children
gain independence and are able to make decisions by themselves. However, on a large time scale, there are so many
uncertainties between parents and children over the consistency of their values and common interests, which may
involve family relationships, the autonomy of children and
other social issues. ③ Social justice and equal access to
technology. The clinical application of gene editing technology is affected by such factors as region, race, public
health service coverage, scientific and technological development, and socioeconomic status, and thus is difficult to be
widely accessible to the masses.
(3) At the ecological level, gene editing technology poses
a challenge to natural evolution, which destroys the integrity
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and evolution of human genes and alters the entire human
gene pool, leading to uncontrollable risks and consequences.
First, it is difficult to evaluate the multi-generation effect
brought about by the edited genetic inheritance. Germline
gene editing will not only exert unexpected effects on the
individual but also have an unpredictable impact on the offspring, which may increase the risk of catching genetic diseases. Second, gene editing may damage the natural ecology.
Targeted gene selection by people may decrease the diversity
of human genes. In addition, in a broad sense, the possible
eco-environmental problems caused by plants with heterologous genes, safety and regulation relating to gene-edited
food, and indirectly induced legal regulations, can also be
included in the ethical issues of gene editing.

2 International research on ethical issues and
governance of gene editing technology
After the CRISPR technique was firstly used for gene editing in human embryos, scientists from different countries
reached a consensus at the International Summit on Human
Genome Editing. That is, the basic research on gene editing is
allowed to be carried out in human embryos, but it would be
irresponsible to put the technology into clinical use at the
present stage. This is the first international redline for gene
editing research. Hereafter, related ethical issues are studied
and discussed continuously. Particularly, after the birth of
gene-edited babies, countries in the world further clarified
boundaries and regulatory measures, and called for an international consensus and a sound governance system.

2.1 Countries around the world are actively improving laws and regulations related to gene editing
technology
At present, about 30 countries in the world have introduced legislation directly or indirectly banning the clinical
use of gene editing technology [22]. Australia, Canada and
some other countries have brought in legislation banning
gene editing in human embryos (or germ cells) and somatic
cell nuclear transfer, violation of which is often punished by
hefty fines or criminal sanction. The United Kingdom stipulates that a risk assessment by certain professional organizations is a prerequisite to authorized human gene editing.
In addition, more explicit measures have been introduced
on the use of gene editing technology in agriculture. The
United States has revised and interpreted its existing laws and
regulations related to GM technology to exempt gene-edited
crops from strict GM regulation. Japan, Finland, Sweden,

Russia, Brazil and Argentina have also managed gene-edited
plant products as non-GM products. On the contrary, many European countries have regulated gene-edited crops as GM crops.

2.2 International organizations issue consensus
reports to prohibit germline gene editing at present
International organizations, governments, research institutions, academic groups and other agencies have published
research reports on research and application of human
germline gene editing. Most agree that basic research on
human germline gene editing can be carried out, but the
clinical application should be avoided in the short term.
Certain criteria must be met before the clinical application of
gene editing, which involves the overcoming of security and
technical barriers, a social consensus on the application
boundary, and an appropriate and transparent regulatory
mechanism (Table 1).
After the birth of gene-edited babies, countries in the
world further issued statements opposing using gene editing
technology for reproductive purposes. According to the Organizing Committee of the Second International Summit on
Human Genome Editing, to put human germline cell gene
editing into clinical use is highly irresponsible, since the
results of the clinical practice are highly uncertain and
risky [28]. In 2019, the World Health Organization (WHO)
established the Expert Advisory Committee on Developing
Global Standards for Governance and Oversight of Human
Genome Editing. The Committee is responsible for examining the scientific, ethical, social and legal challenges associated with gene editing of human somatic cells and germline
cells (including early embryos), advising and establishing a
registration system, providing a transparent and structured
mechanism for future research (including clinical trials) on
collecting and managing germline and somatic gene editing and
⑤⑥
on-progress research details, and so on . In July 2021, the
Committee issued the Human Genome Editing: A Framework
for Governance and Human Genome Editing: Recommendations, aiming to help countries around the world apply human
gene editing technology safely, effectively and ethically [26,27].

2.3 The academic community calls for stronger
regulation on the clinical application of gene editing
technology
In addition to relevant think tanks and organizations, an
increasing number of scientists have called for a consensus
on the clinical application of gene editing technology and the
formulation of relevant laws and regulations to ensure the
development of technology complies with relevant laws and
regulations and will be healthy, orderly and reasonable (Table 2).

______________________________________

⑤ Heritable Human Genome Editing. The Royal Society; National Academy of Sciences; National Academy of Medicine; International Commission on the
Clinical Use of Human Germline Genome EditingWashington (DC): National Academies Press (US); 2020 Sep 3. (DOI: 10.17226/25665)
⑥ Xinhuanet. WHO plans to develop an international governance framework for human genome editing. (2019–03–20) [2021–03–03].
http://www.xinhuanet.com/world/2019–03/20/c_1124258632.htm.
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Table 1

International consensus reports on the clinical application of gene editing technology

Table 2

Expert consensus on the clinical application of gene editing technology

2.4 Ethical research supports normative development of gene editing
The rapid development of gene editing technology has
caused great changes in biomedical research worldwide, and
the research of ethical issues concerning gene editing has
received great attention as the technology develops. The

searching of articles on ethical research on gene editing from
the Web of Science Core Collection on October 26, 2021
obtained a total of 587 articles, which accounted for less than
2% of the total articles on gene editing. Among these articles,
more than 60% (365 articles in total) were published after
2019, namely after the birth of gene-edited babies. However,
gene editing technology began to be widely applied as early
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as 2013, and the West China Hospital of Sichuan University
carried out the first clinical trial of gene editing in the world
in 2016. This shows that the speed of research on ethical
issues related to gene editing and its impact on technological
development are still insufficient, compared with the development of the technology.
From the perspective of geographical distribution of published articles on gene editing, the top five countries are the
United States (218 articles in total), the United Kingdom
(77), Germany (55), China (47) and Australia (36). The
United States, as the origin country of gene editing technology, has the most publications on ethical issues related
to gene editing. China ranks second in publications on
gene editing technology. China has also carried out relevant ethical research and ranked fourth in the world in the
number of publications on ethical issues related to gene
editing.
From the perspective of content, global research on
ethical issues about gene editing mainly focuses on four
fields. ① Ethical issues concerning human germline cell
gene editing. Human germline cell gene editing is the most
controversial field of ethical research, which generally
focuses on the technical risks, moral disputes, social issues, laws and regulations of various countries and the
exiting consensus of international regulations in this field.
Studies suggest that instead of completely suspending and
banning human germline cell gene editing, it is better to
establish a global research framework that balances risks
and benefits as well as being open, cooperative and complying with relevant rules [33]. ② Ethical issues concerning
human non-germline cell gene editing. Great importance
has been attached to the medical value of somatic cell gene
editing, while the security risks caused by off-target and
other technical shortcomings are widely concerned.
Doudna [34], one of the creators of the technology, also published an article indicating the urgency of further improving
gene editing technology, to ensure that this breakthrough
technology is used with responsibility in the treatment and
prevention of genetic diseases. ③ Ethical issues concerning
animal and plant gene editing in agriculture. The discussion
of ethical issues about non-human cell gene editing mainly
focuses on biosafety. Nearly all the articles recognize the
great value of gene editing in agriculture. However, there are
still challenges of gaining social acceptance from people
against genetic modification [35]. ④ Ethical issues concerning
animal and plant gene editing in ecology. Ethical research in
eco-environment has focused on the feasibility of gene editing as a potential biocontrol tool (such as for killing mosquitoes [36]) and for restoring ecosystems and biodiversity.
Meanwhile, ethical research in this field has also presented
concerns about the impact of gene editing on the ecological
chain, and called for the establishment of relevant regulatory
frameworks [37].

3 Research on ethical issues related to gene
editing technology and construction of ethical
governance system in China
China has achieved significant progress in ethical regulation
and governance of gene editing technology in recent years.

3.1 The effect of laws and regulations on gene editing technology has become stronger
There are strict legal regulations on the application of gene
editing technology in human in China. The Ministry of Science and Technology and Ministry of Health (now the “National Health Commission”) jointly issued the Ethical
Guiding Principles for the Research of Human Embryonic
Stem Cell in 2003, which prohibits any research on reproductive human cloning and specifies that human blastocysts
that have been acquired and used in research should not be
implanted into the reproductive system of humans or other
animals. In the same year, the Ministry of Health issued the
Ethical Principles for Human Assisted Reproductive Technology and Sperm Bank, specifying that patients’ gametes
and embryos should not be disposed of or sold without the
informed consent of the patients. In 2020, the Ministry of
Science and Technology issued the Administrative
Measures for the Safety of Biotechnology Research and
Development, categorizing the research and development
activities involving human gene editing and other gene
engineering with significant risks as the level of high risk
and requiring strict management in research institutions at
all levels.
In recent years, China has laid increasing emphasis on the
construction of ethical regulation and governance system of
emerging biotechnologies such as gene editing technology.
The Plan on Establishing a National Science and Technology
Ethics Committee was adopted at the Ninth Session of the
Central Comprehensively Deepening Reforms Commission.
At the session, it was pointed out that ethics must be valued in
all science and technology activities. The purpose of establishing the Committee is to strength overall planning, guidance and coordination, and promote the establishment of a
science and technology ethical governance system that covers all fields, has clear orientations, complies with relevant
laws and regulations and be coordinated. The Civil Code also
explicitly stipulates that people engaged in medical and scientific research activities related to human genes, human
embryos and other aspects shall abide by laws, administrative
regulations and national rules, and shall not endanger human
health, violate ethics or morals, or damage public interests.
This is the first time that medical and scientific research
activities related to human genes and embryos have been
explicitly stipulated at the legal level of higher rank of legal
effect in China.
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3.2 Meetings have called for stronger ethical regulation on gene editing technology
With the rapid development of gene editing technology,
conferences and discussions over relevant ethical issues have
been held continuously. In June 2016, at the Xiangshan Science Conference, which is themed by the research and application of gene editing technology, it is suggested that
regulatory and ethical research on gene editing technology be
deployed as quickly as possible, strict boundaries are set for
gene editing which could cause great ethical and social issues, and clinical trials and applications be prohibited. In the
first forum of scientific responsibility and responsible science
and the symposium of ethics and responsibilities in gene
editing technology, ethical issues and responsibilities related
to gene editing technology were discussed heatedly. Suggestions on the legislation of gene editing technology and recommendations about improving the professionalism of
researchers engaged in gene editing were put forward.
Gene editing technology has also attracted attention at the
two sessions (the National People’s Congress and the Chinese
People’s Political Consultative Conference), and calls for
related legislation have been growing. In 2019, some representatives at the two sessions proposed that the government
should establish the application boundaries of gene editing
technology, and legislate things that can and cannot be done.
They called for prohibitive and restrictive provisions on
recruitment of people as human subjects for research, and on
the research involving gene-edited embryos, as well as for
harsher punishment for violation of the provisions to ensure
strict management. Bai Chunli, President of Chinese Academy of Sciences and Secretary of the CPC Group at that time,
said to reporters of Science and Technology Daily that clinical
trials and applications of human germline gene editing should
be prohibited before the technology is mature and corresponding social and ethical issues are fully discussed and
resolved, while basic research can be tried. In 2021, some
representatives at the two sessions suggested setting out
Guidelines for Ethical Considerations for relevant research,
according to which judgments can be formed in light of the
original source, production process, indications and other
aspects, and ethical risks can be considered comprehensively
to guide clinical trials/studies. It is also suggested that bioethical norms should be enforced for the research involving
advanced biotechnologies such as gene editing.

3.3 The academic community has paid increasing
attention to the ethical issues about gene editing
In recent years, the Chinese academic community has paid
more attention to the research on ethical issues about gene
editing, and the number of related articles is growing. According to the data in CNKI by October 2021, there had been
more than 500 Chinese publications related to ethical issues

about gene editing. The main research institutions included
the School of Humanities of Huazhong University of Science
and Technology, School of Philosophy of Fudan University,
School of Humanities and Social Sciences of Chinese Academy
of Medical Sciences & Peking Union Medical College, School
of Law of Renmin University of China, Peking University
Health Science Center, Wuhan University of Technology, and so
on. These articles focus on the ethical arguments, ethical reflections, moral principles, ethical review, legal regulations and
other aspects related to gene editing technology involving human embryos, germline cells and so on.
In particular, Chinese scientists and ethicists have published articles in international journals to state their opinions
and attitudes after the birth of gene-edited babies. Many
scientists have appealed the Chinese government for a positive and open attitude towards gene editing technology in
agriculture, and for the timely formulation of related policies,
regulations and rules in healthcare to standardize and guide
the development of gene editing technology, so as to promote
the sustainable and healthy development of gene editing in
China. In 2018, a team of scientists published articles on
Lancet to elaborate on the current situation of gene editing
technology, the ethics of human embryo research, and the
science background of the CCR5 gene and HIV prevention
from perspectives of science ethics, science policies, and
medical, scientific and technical backgrounds respectively,
taking the attitude of the scientific community. Ethicists such
as Lei Ruipeng, Zhai Xiaomei and Qiu Renzong called, on
Nature, for stronger ethical regulation on medical research,
taking the birth of gene-edited babies as an opportunity [38].
They recommended in-depth discussions on the rights and
wrongs of human gene editing, firmly opposed practices in
violation of basic ethics and urged researchers to do right
things in the field of human gene editing [39].

4 Suggestions about the ethical governance
system construction of gene editing technology
While promoting human progress, gene editing technology may also cause potential safety risks and ethical issues
due to misuse and abuse. Thus, efforts from all levels, such as
governments, institutions, the scientific community, industry
associations and the public, should be made to comprehensively and systematically strengthen normative governance,
so as to ensure that the technology complies with the interests
of humans and realizes reasonable, orderly and healthy
development.

4.1 The government should formulate a scientific
and reasonable governance system
(1) A coordinated dialogue mechanism should be established.
Related legislative bodies can organize inter-disciplinary and
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inter-departmental collaboration to construct the governance
system of emerging technologies such as gene editing technology and comprehensively evaluate the current governance
systems (including the legal system, regulatory system, innovation system, and review system). By analyzing technical
characteristics, conceiving technique application scenarios
and predicting the development trends of the technique, the
technical governance systems can be upgraded for different
objects, such as humans, animals, plants and microorganisms, so as to meet the needs of the rapid development of the
technology.
(2) A risk-reward evaluation system should be established.
For the strategic layout of the technology, in addition to the
evaluation of the scientific significance, the economic and
social significance, especially such potential risks to life
ethics, biosafety and biosecurity should also be comprehensively assessed before funding related research
projects.
(3) The Guidelines for Medical Research on Gene Editing
Technology are recommended. For research on the medical
application of gene editing technology, such as therapies or
drugs research and development, it is recommended to develop a technical route for preclinical research on gene editing technology, determine the methods, criteria, technologies,
and tools used for the safety evaluation of the clinical application of gene editing, and further formulate related management norms on this basis.

4.2 Research institutions should assume the principal responsibility for management and
supervision
Research institutions are the first subject of responsibility
for the governance of emerging technologies such as gene
editing technology [40]. In December 2018, the Ministry of
Education of China issued the Notice on Self-inspection of
Gene Editing-related Research Projects in Colleges and
Universities, requiring colleges and universities to organize
and conduct self-inspection of gene editing-related research
projects. Charters, working systems and working procedures
of ethics committees of colleges and universities should also
be reported during self-inspection.
(1) The management and supervision systems in relevant
research institutions should be improved. Within the framework of national laws and regulations, guidelines and systems should be developed for standardizing the scientific
research in research institutions. Ethics committees be established to take effective measures to ensure that ethic review can be conducted independently.
(2) Educational and training courses should be set up for
researchers and related managers. Ethic reviewers should
always maintain a fair and objective attitude and possess
ethical professionalism so as to create a normative research
environment and governance atmosphere.

4.3 Ethical regulation should be conducted according to local conditions
Scientific research and ethics regulation are always developing cooperatively during their interactions. The research applying gene editing technology should be conducted
within the existing ethical regulatory framework, while the
technological progress will also cause new ethical issues.
These issues, on the one hand, bring new challenges to the
ethic regulation system, on the other hand, help the ethic
regulation system to be more precise and well-rounded in the
process of dialogues and discussions.
(1) More targeted ethics regulatory approaches should be
supplemented. Opinions in different countries are divided
over the boundaries of the application of gene editing technology in human embryos. Some believe that this should be
completely banned, while others consider that this should be
suspended on certain conditions instead of being totally
banned. For new ethical challenges caused by gene editing
technology, we should study the development pattern of the
technology itself and the characteristics of related ethical
issues, and supplement more targeted ethical regulation approaches within the existing regulatory framework.
(2) A long-term mechanism of studying and a national
safeguarding ethics regulation on new technologies should be
established. Complying with the relevant national laws and
regulations, ethicists, scientists, sociologists and jurists
should be jointly engaged in ethical governance. At the advent of emerging technologies, it is essential to launch relevant ethical research projects in time, study the ethical issues
and formulate special codes of ethics based on the characteristics of new technologies, specific development patterns,
application fields and scenarios, while ensuring precise and
effective regulation.

4.4 The scientific community should bear in mind
its mission and strengthen self-discipline
Researchers, as the source of new technological innovations such as gene editing technology, have the responsibility
to avoid or reduce research risks and harm.
(1) Researchers should bear in mind the lofty mission of
promoting human progress. They should conduct scientific
research for the benefit of all humans, publicize truths to the
mass, always protect the benefits of the public, and only do
the right things.
(2) Researchers should strengthen self-discipline and actively participate in educational and training courses related
to ethics. While ensuring their research complying with the
overall benefits and needs of humans, they should understand
and abide by related regulations, guidelines, and take safety
measures. They should fully understand the possibilities of
abuse and misuse of their research, identify ethical issues,
master approaches to ethical analysis and making ethic-related
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decisions, and regularly evaluate the biosafety risks of their
research projects to timely adjust and reduce risks. In
addition, they should bear their responsibility for educating and training others, and control the safety risks within
their capacity. This is the social responsibility of scientists.

4.5 Other participants should jointly promote the
construction of the governance ecosystem
In addition to governments, regulators, research institutions and the scientific community, other participants involved in the development of emerging technologies such as
gene editing technology can also promote the normative
governance of the technologies.
(1) Ethical issues can be discussed comprehensively and
extensively from multiple links and levels. The supervision,
management and standardization in multiple links involving
the application of gene editing technology, such as funding,
intellectual property management, experimental material
management, paper publication, peer review, result transformation and even medical services, are also important parts
of the construction of the governance ecology.
(2) A public dialogue platform can be built. In terms of
science popularization, we should improve the ability of
research institutions to popularize science and give full play
to the role of media in guiding the public through the ethics
issues concerning gene editing. While strengthening science
popularization with multiple media, we should also standardize the wording of media so that the public can have a
comprehensive and objective understanding of the advantages and possible risks of gene editing technology.
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